PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

Pneumococcal Vaccine Serotypes

With their recommended dose of PNEUMOVAX 23, patients will be vaccinated against additional pneumococcal serotypes not contained in PCV134

Pneumococcal Serotypes Contained in PNEUMOVAX 23 (PPSV23) and Prevnar 13 (PCV13)5

PNEUMOVAX 23 can help prevent pneumococcal disease caused by 23 serotypes

Serotypes Contained in PPSV23 and PCV13
Serotypes Contained in PPSV23 and PCV13

Serotype unique to PCV13

Serotypes contained in both vaccines

Serotypes unique to PNEUMOVAX 23

PCV13=13-valent pneumococcal conjugate vaccine;

PPSV23=23-valent pneumococcal polysaccharide vaccine.

PNEUMOVAX 23 (PPSV23) will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

All brands mentioned are the trademarks of their respective owners.

Vaccine Serotypes and IPD Cases in Adult Patients

The serotypes contained in PNEUMOVAX 23 accounted for a greater percentage of invasive pneumococcal disease (IPD) cases compared to the percentage of IPD cases caused by serotypes in PCV134

Percentage of IPD cases caused by serotypes in each vaccine—United States 20164

Patients Aged 65 Years and Older

Patients Aged 65 Years and Older: ~38% of Invasive Pneumococcal Disease Cases Were Caused By the 11 Unique Serotypes in PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent)4

% IPD cases due to serotypes in PNEUMOVAX 23 (PPSV23)

% IPD cases due to serotypes in PCV13

Data derived from the Active Bacterial Core Surveillance Data, unpublished.

The figure depicts CDC epidemiologic data and does not reflect the efficacy of the respective vaccines.

Patients Aged Under 19-64 Years

Patients aged 19- 64 Years: ~50% of Invasive Pneumococcal Disease Cases Were Caused by the 11 Unique Serotypes in PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent)4

% IPD cases due to serotypes in PNEUMOVAX 23 (PPSV23)

% IPD cases due to serotypes in PCV13

Data derived from the Active Bacterial Core Surveillance Data, unpublished.

The figure depicts CDC epidemiologic data and does not reflect the efficacy of the respective vaccines.

ref4

Reference

  1. Centers for Disease Control and Prevention (CDC). Pneumococcal disease: surveillance and reporting. cdc.gov/pneumococcal/surveillance.html. Updated August 1, 2018. Accessed November 12, 2019.
ref5

Reference

  1. Prevnar 13 [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2019.

Indication for PNEUMOVAX 23

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.
Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Do not administer PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.

Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals cannot be ruled out.

Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

For subjects aged 65 years or older in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination than following initial vaccination.

Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

Before administering PNEUMOVAX 23, please read the accompanying Prescribing Information. The Patient Information also is available.

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.


US-PNX-00807 02/20